US stock futures dip as Nvidia earnings spark little cheer
BOSTON—Amy Elazzouzi, Senior Vice President of Finance at Aura Biosciences , Inc. (NASDAQ:AURA), recently sold 897 shares of the company’s common stock, according to a filing with the Securities and Exchange Commission. The shares were sold at an average price of $5.49, totaling approximately $4,924. The transaction comes as the stock trades significantly below its 52-week high of $12.38, having declined nearly 48% over the past six months. According to InvestingPro, analysts maintain a strong buy consensus with price targets ranging from $19 to $25.
The sale was conducted to cover tax withholding obligations related to the vesting of restricted stock units, as noted in the filing. Following this transaction, Elazzouzi holds 81,381 shares in the company. The shares were sold in multiple transactions, with prices ranging from $5.49 to $5.57. The company maintains a strong liquidity position with a current ratio of 10.77 and holds more cash than debt on its balance sheet. Want deeper insights into insider trading patterns and 8 additional key financial metrics? Check out InvestingPro for comprehensive analysis.
In other recent news, Aura Biosciences announced positive outcomes from its Phase 1 trial of bel-sar for non-muscle invasive bladder cancer (NMIBC), showcasing promising clinical activity and a favorable safety profile. The trial results, presented at the 40th Annual European Association of Urology Congress, revealed that bel-sar achieved complete responses in several patients, with notable tumor shrinkage and minimal adverse events. Meanwhile, H.C. Wainwright raised its price target for Aura Biosciences to $25, citing progress in the development of bel-sar for early-stage choroidal melanoma, which is being evaluated in a Phase 3 trial. The firm highlighted the potential of bel-sar to fill a significant treatment gap, forecasting strong sales growth if successful. JMP Securities also revised its price target for Aura Biosciences, adjusting it to $19 while maintaining a Market Outperform rating. The adjustment was based on positive feedback regarding bel-sar’s Phase 1 data and its potential in treating uveal melanoma. Additionally, Aura Biosciences expanded its Board of Directors by appointing Teresa Bitetti, an experienced oncology leader, which is expected to bolster the company’s strategic direction. These developments reflect ongoing advancements in Aura Biosciences’ clinical pipeline and strategic positioning in the oncology sector.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.